Chinese General Practice ›› 2023, Vol. 26 ›› Issue (17): 2155-2161.DOI: 10.12114/j.issn.1007-9572.2022.0904
• Traditional Chinese Medicine • Previous Articles Next Articles
Received:
2022-12-02
Revised:
2023-01-15
Published:
2023-06-15
Online:
2023-02-23
Contact:
XU Guihua
通讯作者:
徐桂华
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0904
组别 | 例数 | 年龄( | 性别(男/女) | 受教育程度(小学及以下/中学或中专/大专或本科/研究生及以上) | H-Y分期〔M(P25,P75),级〕 | 服药情况(多巴丝肼/多巴丝肼+普拉克索/多巴丝肼+咪多吡/多巴丝肼+甲磺酸雷沙吉兰/多巴丝肼+普拉克索+金刚烷) | 中医证候(痰热动风证/血瘀动风证/肝肾不足证/阴阳两虚证) | 就诊医院(中医院/西医院) |
---|---|---|---|---|---|---|---|---|
对照组 | 16 | 66.1±7.4 | 8/8 | 0/10/5/1 | 1.5(1.5,2.0) | 3/8/1/2/2 | 8/2/4/2 | 8/8 |
观察组 | 16 | 64.8±9.3 | 9/7 | 1/8/6/1 | 1.5(1.5,1.5) | 4/7/2/1/2 | 8/4/2/2 | 7/9 |
检验统计量值 | -0.419a | —b | 1.528b | -0.871 | 1.223b | 1.456b | —b | |
P值 | 0.678 | 1.000 | 0.851 | 0.384 | 1.000 | 0.751 | 1.000 |
Table 1 Comparison of baseline data of two groups
组别 | 例数 | 年龄( | 性别(男/女) | 受教育程度(小学及以下/中学或中专/大专或本科/研究生及以上) | H-Y分期〔M(P25,P75),级〕 | 服药情况(多巴丝肼/多巴丝肼+普拉克索/多巴丝肼+咪多吡/多巴丝肼+甲磺酸雷沙吉兰/多巴丝肼+普拉克索+金刚烷) | 中医证候(痰热动风证/血瘀动风证/肝肾不足证/阴阳两虚证) | 就诊医院(中医院/西医院) |
---|---|---|---|---|---|---|---|---|
对照组 | 16 | 66.1±7.4 | 8/8 | 0/10/5/1 | 1.5(1.5,2.0) | 3/8/1/2/2 | 8/2/4/2 | 8/8 |
观察组 | 16 | 64.8±9.3 | 9/7 | 1/8/6/1 | 1.5(1.5,1.5) | 4/7/2/1/2 | 8/4/2/2 | 7/9 |
检验统计量值 | -0.419a | —b | 1.528b | -0.871 | 1.223b | 1.456b | —b | |
P值 | 0.678 | 1.000 | 0.851 | 0.384 | 1.000 | 0.751 | 1.000 |
组别 | 例数 | MDS-UPDRS Ⅲ评分 | NMSS评分 | ||||
---|---|---|---|---|---|---|---|
治疗前 | 治疗3个月 | 随访1个月 | 治疗前 | 治疗3个月 | 随访1个月 | ||
对照组 | 16 | 23.1±9.3 | 16.8±6.0a | 14.9±5.1ab | 39.1±25.1 | 30.5±21.2a | 31.8±20.7a |
观察组 | 16 | 25.8±11.1 | 11.1±4.1a | 11.5±3.8a | 46.8±27.3 | 6.9±3.6a | 8.8±2.1ab |
差值的95%CI | (-4.1,9.6) | (-9.1,-2.2) | (-6.4,-0.4) | (-10.0,25.2) | (-33.8,-13.4) | (-32.9,-13.2) | |
P值 | 0.433 | 0.001 | 0.029 | 0.396 | <0.001 | <0.001 |
Table 2 Comparison of MDS-UPDRS Ⅲ,NMSS scores between the two groups before and after treatment
组别 | 例数 | MDS-UPDRS Ⅲ评分 | NMSS评分 | ||||
---|---|---|---|---|---|---|---|
治疗前 | 治疗3个月 | 随访1个月 | 治疗前 | 治疗3个月 | 随访1个月 | ||
对照组 | 16 | 23.1±9.3 | 16.8±6.0a | 14.9±5.1ab | 39.1±25.1 | 30.5±21.2a | 31.8±20.7a |
观察组 | 16 | 25.8±11.1 | 11.1±4.1a | 11.5±3.8a | 46.8±27.3 | 6.9±3.6a | 8.8±2.1ab |
差值的95%CI | (-4.1,9.6) | (-9.1,-2.2) | (-6.4,-0.4) | (-10.0,25.2) | (-33.8,-13.4) | (-32.9,-13.2) | |
P值 | 0.433 | 0.001 | 0.029 | 0.396 | <0.001 | <0.001 |
组别 | 例数 | IL-1β〔M(P25,P75),ng/L〕 | NF-κB( | ||||||
---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗3个月 | Z配对值 | P值 | 治疗前 | 治疗3个月 | t配对值 | P值 | ||
对照组 | 16 | 82.8(70.7,90.1) | 70.4(66.0,72.9) | 4.090 | 0.001 | 512.6±83.7 | 425.8±65.6 | 2.690 | 0.017 |
观察组 | 16 | 82.6(71.0,90.0) | 51.3(46.9,65.5) | 7.475 | <0.001 | 478.4±79.7 | 336.1±69.8 | 5.725 | <0.001 |
t(Z)值 | 0.013a | -3.166a | 1.184 | 3.749 | |||||
P值 | 0.990 | 0.002 | 0.246 | 0.001 |
Table 3 Serum IL-1β,NF-κB levels between the two groups before and after treatment
组别 | 例数 | IL-1β〔M(P25,P75),ng/L〕 | NF-κB( | ||||||
---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗3个月 | Z配对值 | P值 | 治疗前 | 治疗3个月 | t配对值 | P值 | ||
对照组 | 16 | 82.8(70.7,90.1) | 70.4(66.0,72.9) | 4.090 | 0.001 | 512.6±83.7 | 425.8±65.6 | 2.690 | 0.017 |
观察组 | 16 | 82.6(71.0,90.0) | 51.3(46.9,65.5) | 7.475 | <0.001 | 478.4±79.7 | 336.1±69.8 | 5.725 | <0.001 |
t(Z)值 | 0.013a | -3.166a | 1.184 | 3.749 | |||||
P值 | 0.990 | 0.002 | 0.246 | 0.001 |
组别 | 例数 | 治疗3个月 | 随访1个月 | ||||||
---|---|---|---|---|---|---|---|---|---|
无效 | 有效 | 显效 | 临床控制 | 无效 | 有效 | 显效 | 临床控制 | ||
对照组 | 16 | 6 | 10 | 0 | 0 | 2 | 14 | 0 | 0 |
观察组 | 16 | 2 | 2 | 10 | 2 | 2 | 2 | 11 | 1 |
Z值 | -3.651 | -3.468 | |||||||
P值 | <0.001 | 0.001 |
Table 4 Comparison of clinical efficacy between the two groups after 3 months of treatment and 1 month of follow-up
组别 | 例数 | 治疗3个月 | 随访1个月 | ||||||
---|---|---|---|---|---|---|---|---|---|
无效 | 有效 | 显效 | 临床控制 | 无效 | 有效 | 显效 | 临床控制 | ||
对照组 | 16 | 6 | 10 | 0 | 0 | 2 | 14 | 0 | 0 |
观察组 | 16 | 2 | 2 | 10 | 2 | 2 | 2 | 11 | 1 |
Z值 | -3.651 | -3.468 | |||||||
P值 | <0.001 | 0.001 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
杨敏,岳容兆,张沁,等. 基于文献计量学探析单一刮痧疗法的临床病症谱[J]. 护理研究,2019,33(8):1320-1324. DOI:10.12102/j.issn.1009-6493.2019.08.009.
|
[10] |
|
[11] |
中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志,2016,49(4):268-271. DOI:10.3760/cma.j.issn.1006-7876.2016.04.002.
|
[12] |
|
[13] |
中华全国中医学会老年医学会.中医老年颤证诊断和疗效评定标准[J].北京中医学院学报,1992,15(4):39-41.
|
[14] |
曲艳,李晓红,孙亚南,等. 汉化版MDS-UPDRS与传统UPDRS评测帕金森病的比较分析[J]. 中国康复理论与实践,2019,25(8):936-939. DOI:10.3969/j.issn.1006-9771.2019.08.010.
|
[15] |
|
[16] |
郑筱萸. 中药新药临床研究指导原则:试行[M]. 北京:中国医药科技出版社,2002:29-31.
|
[17] |
国家市场监督管理总局,国家标准化管理委员会. 经穴名称与定位:GB/T 12346—2021[S]. 北京:中国标准出版社,2021.
|
[18] |
周素英. 足反射法结合刮痧治疗帕金森氏病一例[J]. 双足与保健,2001(3):33.
|
[19] |
苏巧珍,孙玉芝,连新福,等. 施氏砭术综合疗法治疗29例帕金森病[J]. 广东医学,2012,33(12):1834-1835. DOI:10.13820/j.cnki.gdyx.2012.12.059.
|
[20] |
|
[21] |
|
[22] |
张欣,王谦鑫宏,赵慧杰,等. 基于皮肤免疫理论的"足太阳膀胱经主一身之表"的实验研究[J]. 时珍国医国药,2016,27(1):232-234.
|
[23] |
|
[24] | |
[25] |
|
[26] |
|
[27] |
|
[1] | ZHANG Yutong, WANG Qiuqin, XU Yuchen, WENG Heng, LIANG Yongqi, WANG Lulu, WANG Qing, XU Guihua. Factors Affecting Pain in Patients with Parkinson's Disease: a Systematic Review [J]. Chinese General Practice, 2023, 26(14): 1766-1774. |
[2] | Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022) [J]. Chinese General Practice, 2023, 26(14): 1671-1691. |
[3] | YAO Huijuan, YANG Yu, XU Ajing. Interpretation of Diabetes Management in Chronic Kidney Disease: a Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) [J]. Chinese General Practice, 2023, 26(12): 1415-1421. |
[4] | DONG Linrui, CHANG Qingqing, MA Jianjun, LIU Chuanze, GUO Dashuai, LI Xiaohuan, FAN Yongyan, LI Dongsheng. Correlation between Autonomic Dysfunction and Cognitive Impairment in Patients with Parkinson's Disease [J]. Chinese General Practice, 2023, 26(12): 1450-1455. |
[5] | TIAN Maosheng, GAO Jihua, XU Jiancheng, QI Wenyue, WANG Linyue, GAO Ce. Clinical Effect of Mussel Adhesive Protein with Tongyangxiao Lotion in Grades 1 and 2 Mixed Hemorrhoids [J]. Chinese General Practice, 2023, 26(08): 955-962. |
[6] | HU Shuwei, OU Wei, WANG Zhi, PENG Juan. Eye Movement Desensitization and Reprocessing versus Sertraline in the Treatment of Depressed Adolescents with Childhood Trauma [J]. Chinese General Practice, 2023, 26(06): 692-698. |
[7] | SONG Pingan, CHEN Xiaoliang, YAO Yuan, GAO Jin, YANG Yang, CUI Hongchun, ZHANG Yi. Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(02): 241-247. |
[8] | ZENG Yuan, WANG Guohua, YANG Yong. Curative Effect of Patient-controlled Intravenous Analgesia with Hydromorphone, Sufentanil or Morphine in Treatment of Refractory Cancer Pain with Dysphagia [J]. Chinese General Practice, 2022, 25(36): 4537-4545. |
[9] | Hanwen YANG, Yaoxian WANG, Qiaoru WU, Jiale ZHANG, Runze YAN, Xiaona WANG, Zhen WANG, Weiwei SUN. Efficacy and Safety of Xiezhuoxiaozheng Therapy in Diabetic Kidney Disease: a Clinical Study [J]. Chinese General Practice, 2022, 25(26): 3252-3257. |
[10] | Gen HUANG, Huimin CAO, Gang YU. Novel Developments in Hypomimia in Parkinson's Disease [J]. Chinese General Practice, 2022, 25(20): 2558-2562. |
[11] | Pengxiang ZHANG, Lin ZENG, Lu MENG, Qian HUANG, Gaoxiang WANG, Deliang LIU. New Research Progress of the Novel Target Drugs for the Treatment of Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2022, 25(20): 2551-2557. |
[12] | Min CHEN, Xin XIE, Yunzhou SHI, Hui ZHENG, Qiaofeng WU, Haiyan ZHOU, Zhigang LI, Shuguang YU. Research Status and Thoughts on the Comparative Effect of Traditional Chinese Medicine in the Treatment of IBS-D [J]. Chinese General Practice, 2022, 25(15): 1795-1800,F01. |
[13] | Ling LI, Huijuan ZHANG. Recent Developments in Pituitary-directed Medical Treatment for Cushing's Disease [J]. Chinese General Practice, 2022, 25(14): 1789-1794. |
[14] |
CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia.
Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia [J]. Chinese General Practice, 2022, 25(08): 957-962. |
[15] |
SHI Xiaoxue, ZHENG Jinhua, MA Jianjun, WANG Zhidong, SUN Wenhua, LI Mingjian, HUANG Shen, HU Shiyu, LI Dongsheng.
Risk Factors of Dysphagia in Parkinson's Disease [J]. Chinese General Practice, 2022, 25(06): 669-674. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||